OncoMatch/Clinical Trials/NCT06592638
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
Is NCT06592638 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ZG006 for small cell lung cancer.
Treatment: ZG006 — This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recommended dose for the subsequent studies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: DLL3 expression (positive)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatments
who failed or intolerant to available standard treatments
Cannot have received: chemotherapy
Chemotherapy ... ≤ 4 weeks before the study entry
Cannot have received: biotherapy
biotherapy ... ≤ 4 weeks before the study entry
Cannot have received: endocrine therapy
Exception: except for hormone replacement
endocrine therapy (except for hormone replacement) ... ≤ 4 weeks before the study entry
Cannot have received: biological targeted medicines
biological targeted medicines ≤ 4 weeks before the study entry
Cannot have received: local palliative radiotherapy
Local palliative radiotherapy ... ≤ 2 weeks (or 5 half-lives, whichever is longer) before the study entry
Cannot have received: small molecule targeted therapy
small molecule targeted therapy ≤ 2 weeks (or 5 half-lives, whichever is longer) before the study entry
Cannot have received: systemic immunosuppressive medications (corticosteroid)
Exception: doses > 10 mg/day prednisone or equivalent dose within 14 days prior to the study entry
Systemic immunosuppressive medications, such as corticosteroid (doses > 10 mg/day prednisone or equivalent dose) within 14 days prior to the study entry
Cannot have received: vaccines against viral infections (COVID-19, influenza, varicella)
Use of any vaccines against viral infections (COVID-19, influenza, varicella, etc.) within 4 weeks of study entry
Cannot have received: blood transfusion
Patients received any blood transfusion ... within 14 days prior to study entry
Cannot have received: EPO
Patients received any ... EPO ... within 14 days prior to study entry
Cannot have received: G-CSF
Patients received any ... G-CSF ... within 14 days prior to study entry
Cannot have received: albumin infusion
Patients received any ... albumin infusion ... within 14 days prior to study entry
Cannot have received: renal replacement therapy
Patients received any ... renal replacement therapy within 14 days prior to study entry
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Zelgen Site 105 · Orange, California
- Zelgen Site 102 · Plantation, Florida
- Zelgen Site 103 · Lexington, Kentucky
- Zelgen Site 101 · Canton, Ohio
- Zelgen Site 104 · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify